AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] InspireMD, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

On 30 Jul 2025, InspireMD, Inc. (NSPR) director Dr. Gary S. Roubin reported an open-market purchase of 41,322 common shares at $2.42 per share under a private-placement exemption (Securities Act §4(a)(2)). Following the transaction, the director’s directly held position increased to 608,425 shares. No derivative securities were involved, and the filing contains no sales or dispositions.

The single transaction represents an insider adding to his stake rather than trimming holdings, which can be viewed as a signal of personal confidence in the company’s prospects. The form was signed on 01 Aug 2025 by attorney-in-fact Craig Shore.

Il 30 luglio 2025, il direttore di InspireMD, Inc. (NSPR), Dr. Gary S. Roubin, ha comunicato un acquisto sul mercato aperto di 41.322 azioni ordinarie al prezzo di 2,42 $ per azione, effettuato con esenzione da collocamento privato (Securities Act §4(a)(2)). Dopo questa operazione, la posizione detenuta direttamente dal direttore è salita a 608.425 azioni. Non sono stati coinvolti strumenti derivati e la comunicazione non riporta vendite o cessioni.

Questa singola operazione rappresenta un aumento della partecipazione da parte dell’insider, piuttosto che una riduzione, e può essere interpretata come un segnale di fiducia personale nelle prospettive dell’azienda. Il modulo è stato firmato il 01 agosto 2025 dall’avvocato rappresentante Craig Shore.

El 30 de julio de 2025, el director de InspireMD, Inc. (NSPR), Dr. Gary S. Roubin, informó una compra en mercado abierto de 41.322 acciones ordinarias a $2.42 por acción bajo una exención de colocación privada (Securities Act §4(a)(2)). Tras la transacción, la posición directa del director aumentó a 608.425 acciones. No se involucraron valores derivados y la presentación no contiene ventas ni disposiciones.

La transacción única representa que un insider aumenta su participación en lugar de reducirla, lo que puede interpretarse como una señal de confianza personal en las perspectivas de la empresa. El formulario fue firmado el 01 de agosto de 2025 por el apoderado Craig Shore.

2025ë…� 7ì›� 30ì�, InspireMD, Inc. (NSPR)ì� ì´ì‚¬ Dr. Gary S. Roubinì� 사설배정 ë©´ì œ(Securities Act §4(a)(2))ë¥� 통해 주당 2.42달러ì—� 41,322 보통ì£�ë¥� 시장 ë‚� 매수했다ê³� 보고했습니다. 거래 í›� ì´ì‚¬ì� ì§ì ‘ 보유 ì£¼ì‹ ìˆ�µç� 608,425ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 파ìƒìƒí’ˆì€ í¬í•¨ë˜ì§€ 않았으며, 신고서엵ç� 매ë„ë‚� 처분 ë‚´ìš©ì� 없습니다.

ì´ë²ˆ ë‹¨ì¼ ê±°ëž˜µç� ë‚´ë¶€ìžê°€ 보유 ì§€ë¶„ì„ ì¤„ì´ì§€ 않고 오히ë � 늘린 것으ë¡�, 회사ì� ì „ë§ì—� 대í•� ê°œì¸ì � 신뢰ì� 신호ë¡� ë³� ìˆ� 있습니다. 서류µç� 2025ë…� 8ì›� 1ì� ëŒ€ë¦¬ì¸ Craig Shoreì—� ì˜í•´ 서명ë˜ì—ˆìŠµë‹ˆë‹�.

Le 30 juillet 2025, le directeur d’InspireMD, Inc. (NSPR), Dr Gary S. Roubin, a déclaré un achat sur le marché libre de 41 322 actions ordinaires au prix de 2,42 $ par action, bénéficiant d’une exemption de placement privé (Securities Act §4(a)(2)). Suite à la transaction, la position détenue directement par le directeur est passée à 608 425 actions. Aucun instrument dérivé n’était impliqué et le dépôt ne mentionne aucune vente ni cession.

Cette opération unique représente un renforcement de la participation par l’initié plutôt qu’une réduction, ce qui peut être interprété comme un signe de confiance personnelle dans les perspectives de la société. Le formulaire a été signé le 1er août 2025 par le mandataire Craig Shore.

Am 30. Juli 2025 meldete der Direktor von InspireMD, Inc. (NSPR), Dr. Gary S. Roubin, einen Kauf am offenen Markt von 41.322 Stammaktien zum Preis von 2,42 $ pro Aktie unter einer Privatplatzierungsausnahme (Securities Act §4(a)(2)). Nach der Transaktion erhöhte sich die direkt gehaltene Position des Direktors auf 608.425 Aktien. Es waren keine Derivate beteiligt, und die Meldung enthält keine Verkäufe oder Veräußerungen.

Die einzelne Transaktion stellt eine Aufstockung der Beteiligung durch den Insider dar, anstatt eine Reduzierung, was als Zeichen persönlicher Zuversicht in die Aussichten des Unternehmens gewertet werden kann. Das Formular wurde am 01. August 2025 vom Bevollmächtigten Craig Shore unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Director bought 41k NSPR shares at $2.42, boosting holdings to 608k; positive insider signal, modest size.

The Form 4 shows a straightforward purchase with no accompanying sales, suggesting the director is increasing exposure rather than diversifying out. While the 41,322-share block is relatively small versus market float, insider buys—particularly from board members—often align with perceived undervaluation or upcoming milestones. The lack of derivative positions removes complexity and indicates direct balance-sheet commitment. Investors typically view such purchases favorably, though the filing alone does not disclose strategic catalysts or fundamental data.

Il 30 luglio 2025, il direttore di InspireMD, Inc. (NSPR), Dr. Gary S. Roubin, ha comunicato un acquisto sul mercato aperto di 41.322 azioni ordinarie al prezzo di 2,42 $ per azione, effettuato con esenzione da collocamento privato (Securities Act §4(a)(2)). Dopo questa operazione, la posizione detenuta direttamente dal direttore è salita a 608.425 azioni. Non sono stati coinvolti strumenti derivati e la comunicazione non riporta vendite o cessioni.

Questa singola operazione rappresenta un aumento della partecipazione da parte dell’insider, piuttosto che una riduzione, e può essere interpretata come un segnale di fiducia personale nelle prospettive dell’azienda. Il modulo è stato firmato il 01 agosto 2025 dall’avvocato rappresentante Craig Shore.

El 30 de julio de 2025, el director de InspireMD, Inc. (NSPR), Dr. Gary S. Roubin, informó una compra en mercado abierto de 41.322 acciones ordinarias a $2.42 por acción bajo una exención de colocación privada (Securities Act §4(a)(2)). Tras la transacción, la posición directa del director aumentó a 608.425 acciones. No se involucraron valores derivados y la presentación no contiene ventas ni disposiciones.

La transacción única representa que un insider aumenta su participación en lugar de reducirla, lo que puede interpretarse como una señal de confianza personal en las perspectivas de la empresa. El formulario fue firmado el 01 de agosto de 2025 por el apoderado Craig Shore.

2025ë…� 7ì›� 30ì�, InspireMD, Inc. (NSPR)ì� ì´ì‚¬ Dr. Gary S. Roubinì� 사설배정 ë©´ì œ(Securities Act §4(a)(2))ë¥� 통해 주당 2.42달러ì—� 41,322 보통ì£�ë¥� 시장 ë‚� 매수했다ê³� 보고했습니다. 거래 í›� ì´ì‚¬ì� ì§ì ‘ 보유 ì£¼ì‹ ìˆ�µç� 608,425ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 파ìƒìƒí’ˆì€ í¬í•¨ë˜ì§€ 않았으며, 신고서엵ç� 매ë„ë‚� 처분 ë‚´ìš©ì� 없습니다.

ì´ë²ˆ ë‹¨ì¼ ê±°ëž˜µç� ë‚´ë¶€ìžê°€ 보유 ì§€ë¶„ì„ ì¤„ì´ì§€ 않고 오히ë � 늘린 것으ë¡�, 회사ì� ì „ë§ì—� 대í•� ê°œì¸ì � 신뢰ì� 신호ë¡� ë³� ìˆ� 있습니다. 서류µç� 2025ë…� 8ì›� 1ì� ëŒ€ë¦¬ì¸ Craig Shoreì—� ì˜í•´ 서명ë˜ì—ˆìŠµë‹ˆë‹�.

Le 30 juillet 2025, le directeur d’InspireMD, Inc. (NSPR), Dr Gary S. Roubin, a déclaré un achat sur le marché libre de 41 322 actions ordinaires au prix de 2,42 $ par action, bénéficiant d’une exemption de placement privé (Securities Act §4(a)(2)). Suite à la transaction, la position détenue directement par le directeur est passée à 608 425 actions. Aucun instrument dérivé n’était impliqué et le dépôt ne mentionne aucune vente ni cession.

Cette opération unique représente un renforcement de la participation par l’initié plutôt qu’une réduction, ce qui peut être interprété comme un signe de confiance personnelle dans les perspectives de la société. Le formulaire a été signé le 1er août 2025 par le mandataire Craig Shore.

Am 30. Juli 2025 meldete der Direktor von InspireMD, Inc. (NSPR), Dr. Gary S. Roubin, einen Kauf am offenen Markt von 41.322 Stammaktien zum Preis von 2,42 $ pro Aktie unter einer Privatplatzierungsausnahme (Securities Act §4(a)(2)). Nach der Transaktion erhöhte sich die direkt gehaltene Position des Direktors auf 608.425 Aktien. Es waren keine Derivate beteiligt, und die Meldung enthält keine Verkäufe oder Veräußerungen.

Die einzelne Transaktion stellt eine Aufstockung der Beteiligung durch den Insider dar, anstatt eine Reduzierung, was als Zeichen persönlicher Zuversicht in die Aussichten des Unternehmens gewertet werden kann. Das Formular wurde am 01. August 2025 vom Bevollmächtigten Craig Shore unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stuka Paul

(Last) (First) (Middle)
C/O INSPIREMD, INC.
6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)
MIAMI FL 33126

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/30/2025 P 20,661(1) A $2.42(2) 444,195 I(3) See Footnote
Common Stock 360,284 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on July 30, 2025 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").
2. The purchase price per share of common stock in the Private Placement was $2.42.
3. These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
Remarks:
Exhibit 24.1: Power of Attorney
/s/ Craig Shore, Attorney-in-Fact for Paul Stuka 08/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Inspiremd

NASDAQ:NSPR

NSPR Rankings

NSPR Latest News

NSPR Latest SEC Filings

NSPR Stock Data

72.61M
19.27M
18.22%
42.81%
0.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Israel
MIAMI